Readout, drug selection and instillation
Each condition will be investigated in triplicates; triplicates and average will be used for drug selection. Only drugs that reduce viability by 50% or more compared to the vehicle, will be considered. In case that more than one drug reduces viability by 50% or more compared to the vehicle, a pairwise Wilcoxon test will be performed between drug and the vehicle. The drug with the lowest p-value will be selected.Four weeks after TURBT, this selected drug will be used for intravesical instillation. Based on the results of the drug screen in PDO, patients will receive one of either (Epirubicin intravesical (50 mg/50 ml), Mitomycin C intravesical (40 mg/50 ml), Gemcitabine intravesical (1000 ml/50 ml) or Docetaxel intravesical (37.5 mg/50 ml)) once weekly for 6 weeks.